Myriad Genetics Sees Analyst Downgrades and Price Target Cuts

Myriad Genetics faces challenges as analysts lower expectations. With a current average price target down by 18.64%, investor sentiment appears cautious about the company's stock performance.

Date: 03-03-2025

AI Rating: 4

Analyst Overview: Myriad Genetics has recently attracted a variety of analyst opinions, showcasing a mix of bullish and bearish perspectives. Out of 10 analysts, there are 2 bullish ratings, 5 indifferent, and 2 somewhat bearish ratings.

Price Target Adjustments: The average price target for Myriad Genetics currently stands at $17.90, significantly lower than the previous target of $22.00, reflecting a downward trend of 18.64%.

Financial Insights: Myriad Genetics has experienced a revenue decline of approximately -1.27%, indicating challenges in sustaining its top-line earnings compared to its competitors. This slight reduction suggests that the company is struggling to grow in a competitive market.

Net Margin: The report indicates that Myriad Genetics maintains a net margin of -20.18%, which is below industry standards and demonstrates areas for improvement in operational efficiency.

Return Metrics: The company's return on equity (ROE) is reported at -5.93%, alongside a return on assets (ROA) of -4.03%. Both figures are below industry benchmarks, indicating potential inefficiencies in utilizing capital and assets effectively.

Debt Management: An important metric is the company’s debt-to-equity ratio, which is at 0.2, relative to industry norms, signifies a higher amount of debt. This could pose future financial challenges, raising concerns among investors about long-term financial stability.

Stocks: MYGN